APA (7th ed.) Citation

Jun Ma, Donglu Zhao, Bihong Zhen, Yan Xia, Qianyi Gong, & Wendong Chen. (2023). Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma. Becaris Publishing Limited.

Chicago Style (17th ed.) Citation

Jun Ma, Donglu Zhao, Bihong Zhen, Yan Xia, Qianyi Gong, and Wendong Chen. Cost-effectiveness of Obinutuzumab Plus Bendamustine in Chinese Patients with Relapse and Refractory Follicular Lymphoma. Becaris Publishing Limited, 2023.

MLA (9th ed.) Citation

Jun Ma, et al. Cost-effectiveness of Obinutuzumab Plus Bendamustine in Chinese Patients with Relapse and Refractory Follicular Lymphoma. Becaris Publishing Limited, 2023.